Durect begins phase III studies on Alzheimer's treatment

By E. Janene Geiss

Philadelphia, Oct. 14 - Durect Corp. announced Friday the start of phase III clinical studies for its Durin-based leuprolide program in development with Voyager Pharmaceuticals for the treatment of Alzheimer's disease.

Alzheimer's, an incurable neurodegenerative disorder, affects four million Americans and has a market potential in excess of $10 billion, Durect said in a press release.

The phase III program will consist of about 1,100 patients in two randomized 56-week clinical trials using Memryte as an adjunctive therapy with acetyle cholinesterase inhibitors for the treatment of mild to moderate Alzheimer's disease, officials said.

Durect's Durin biodegradable implant technology is a platform for parenteral delivery of drugs for periods of weeks to six months.

Durect, a specialty pharmaceutical company based in Cupertino, Calif., focuses on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic or episodic diseases. The company has five disclosed on-going development programs, of which four are in collaboration with pharmaceutical partners.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.